KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Tax Provisions (2016 - 2025)

Vertex Pharmaceuticals has reported Tax Provisions over the past 15 years, most recently at $139.9 million for Q4 2025.

  • Quarterly results put Tax Provisions at $139.9 million for Q4 2025, down 37.4% from a year ago — trailing twelve months through Dec 2025 was $690.0 million (down 12.0% YoY), and the annual figure for FY2025 was $690.0 million, down 12.0%.
  • Tax Provisions for Q4 2025 was $139.9 million at Vertex Pharmaceuticals, down from $215.9 million in the prior quarter.
  • Over the last five years, Tax Provisions for VRTX hit a ceiling of $257.9 million in Q4 2022 and a floor of -$111.2 million in Q2 2021.
  • Median Tax Provisions over the past 5 years was $192.2 million (2022), compared with a mean of $176.6 million.
  • Biggest five-year swings in Tax Provisions: tumbled 789.6% in 2021 and later skyrocketed 292.36% in 2022.
  • Vertex Pharmaceuticals' Tax Provisions stood at $100.8 million in 2021, then soared by 155.85% to $257.9 million in 2022, then plummeted by 30.67% to $178.8 million in 2023, then increased by 25.0% to $223.5 million in 2024, then tumbled by 37.4% to $139.9 million in 2025.
  • The last three reported values for Tax Provisions were $139.9 million (Q4 2025), $215.9 million (Q3 2025), and $250.1 million (Q2 2025) per Business Quant data.